Medico Remedies is currently trading at Rs. 48.70, up by 0.32 points or 0.66% from its previous closing of Rs. 48.38 on the BSE.
The scrip opened at Rs. 48.75 and has touched a high and low of Rs. 48.75 and Rs. 48.00 respectively. So far 152 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 56.99 on 25-May-2026 and a 52 week low of Rs. 31.00 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 52.85 and Rs. 44.65 respectively. The current market cap of the company is Rs. 401.64 crore.
The promoters holding in the company stood at 61.38%, while Institutions and Non-Institutions held 0.08% and 38.54% respectively.
Medico Remedies has secured order worth $1.41 million (around Rs 13.38 crore) from PROMESE/CAL, Dominican Republic. The company has secured the order to supply tablets, capsules and dry syrups to PROMESE/CAL and will complete the supply of the full order within 3 months.
PROMESE/CAL (Programa de Medicamentos Esenciales y Central de Logistica) is the program responsible for the centralized purchase and distribution of medicines, health supplies and laboratory reagents that meets the demand of the National Public Health System in the Country of Dominican Republic.
Medico Remedies is a leading manufacturer and exporter of pharmaceutical formulations including tablets, capsules and suspensions.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1944.20 |
| Dr. Reddys Labs. | 1164.20 |
| Cipla | 1465.15 |
| Lupin | 2399.55 |
| Zydus Lifesciences | 1101.25 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: